United States - English - NLM (National Library of Medicine)

uihc – p e t imaging center - edotreotide gallium ga-68 (unii: y68179sy2l) (edotreotide gallium ga-68 - unii:y68179sy2l) - ga 68 dotatoc injection is indicated for use with positron emission tomography (pet) for the localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult and pediatric patients. none risk summary there are no available data on the use of ga 68 dotatoc injection in pregnant women to identify a risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with ga 68 dotatoc. however, all radiopharmaceuticals, including ga 68 dotatoc injection have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. if considering ga 68 dotatoc injection administration to a pregnant woman, inform the patient of the potential for adverse pregnancy outcomes based on the radiation dose from ga 68 dotatoc injection and the gestational timing of exposure. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregn

United States - English - NLM (National Library of Medicine)

curium us llc - gallium chloride ga-67 (unii: a04b19o2b0) (gallium cation ga-67 - unii:99t03j52w0) - gallium cation ga-67 2 mci in 1 ml - gallium citrate ga 67 injection may be useful to demonstrate the presence and extent of hodgkin's disease, lymphoma, and bronchogenic carcinoma. positive gallium ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. gallium citrate ga 67 injection may be useful as an aid in detecting some acute inflammatory lesions. none.

United States - English - NLM (National Library of Medicine)

lantheus medical imaging, inc. - gallium citrate ga-67 (unii: 4ljk511z86) (gallium cation ga-67 - unii:99t03j52w0) - gallium cation ga-67 2.0 mci in 1 ml - gallium citrate ga 67 injection may be useful in demonstrating the presence of the following malignancies: hodgkins disease, lymphomas and bronchogenic carcinoma. positive ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. gallium citrate ga 67 injection may be useful as an aid in detecting some acute inflammatory lesions. none known.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - tramadol hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - tramadol hydrochloride -

United States - English - NLM (National Library of Medicine)

advanced accelerator applications usa, inc - dotatate (unii: mrl3739g66) (dotatate gallium ga-68 - unii:9l17y0h71p) - dotatate 40 ug - netspot, after radiolabeling with gallium-68, is indicated for use with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult and pediatric patients. none. risk summary there are no studies with gallium ga 68 dotatate in pregnant women to inform any drug-associated risks; however, radioactive emissions, including those from gallium ga 68 dotatate, can cause fetal harm. animal reproduction studies have not been conducted with gallium ga 68 dotatate. in the u.s. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. risk summary there is no information on the presence of gallium ga 68 dotatate in human milk, the effect on the breastfed child, or the effect on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for gallium ga 68 dotatate injection and a

United States - English - NLM (National Library of Medicine)

purminerals - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51) - octinoxate 50 mg in 1 ml - sunscreen helps prevent sunburn.

United States - English - NLM (National Library of Medicine)

ucla biomedical cyclotron - gallium ga-68 gozetotide (unii: zj0ekr6m10) (gallium ga-68 gozetotide - unii:zj0ekr6m10) - gallium ga 68 gozetotide injection is indicated for positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer: - with suspected metastasis who are candidates for initial definitive therapy. - with suspected recurrence based on elevated serum prostate-specific antigen (psa) level. none risk summary gallium ga 68 gozetotide injection is not indicated for use in females. there are no available data with gallium ga 68 gozetotide injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. all radiopharmaceuticals, including gallium ga 68 gozetotide injection, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. animal reproduction studies have not been conducted with gallium ga 68 gozetotide. risk summary gallium ga 68 gozetotide injection is not indicated for use in females. there are no data

United States - English - NLM (National Library of Medicine)

ucsf radiopharmaceutical facility - gallium ga-68 gozetotide (unii: zj0ekr6m10) (gallium ga-68 gozetotide - unii:zj0ekr6m10) - gallium ga 68 gozeotide injection is indicated for positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer: - with suspected metastasis who are candidates for initial definitive therapy. - with suspected recurrence based on elevated serum prostate-specific antigen (psa) level. none risk summary gallium ga 68 gozetotide injection is not indicated for use in females. there are no available data with gallium ga 68 gozetotide injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. all radiopharmaceuticals, including gallium ga 68 gozetotide injection, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. animal reproduction studies have not been conducted with gallium ga 68 gozetotide injection. risk summary gallium ga 68 gozetotide injection is not indicated for use in females. there ar

United States - English - NLM (National Library of Medicine)

advanced accelerator applications usa, inc - gozetotide (unii: 9ag41l3aoq) (gozetotide - unii:9ag41l3aoq) - locametz, after radiolabeling with gallium-68, is indicated for positron emission tomography (pet) of prostate-specific membrane antigen (psma)-positive lesions in men with prostate cancer: - with suspected metastasis who are candidates for initial definitive therapy. - with suspected recurrence based on elevated serum prostate-specific antigen (psa) level. - for selection of patients with metastatic prostate cancer, for whom lutetium lu 177 vipivotide tetraxetan psma-directed therapy is indicated. none. risk summary locametz is not indicated for use in females. there are no available data with gallium ga 68 gozetotide use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. all radiopharmaceuticals, including locametz, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of radiation dose. animal reproduction studies have not been conducted with gallium ga 68 gozetotide. risk summar